scholarly journals Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Seidu A. Richard
Keyword(s):  
Peripheral Blood ◽  
Low Dose ◽  
Suppressor Cells ◽  
Good Prognosis ◽  
Myeloid Derived Suppressor Cells ◽  
Heterogeneous Cluster ◽  
Multiple Tumor ◽  
Glioma Growth ◽  
Almost All ◽  
The Brain

Glioblastoma (GBM) is a malignant and aggressive central nervous tumor that originates from astrocytes. These pathogenic astrocytes divide rapidly and are sustained by enormous network of blood vessels via which they receive requisite nutrients. It well proven that GBM microenvironment is extremely infiltrated by myeloid-derived suppressor cells (MDSCs). MDSCs are a heterogeneous cluster of immature myeloid progenitors. They are key mediates in immune suppression as well as sustenance glioma growth, invasion, vascularization, and upsurge of regulatory T cells via different molecules. MDSCs are often elevated in the peripheral blood of patients with GBM. MDSCs in the peripheral blood as well as those infiltrating the GBM microenvironment correlated with poor prognosis. Also, an upsurge in circulating MDSCs in the peripheral blood of patients with GBM was observed compared to benign and grade I/II glioma patients. GBM patients with good prognosis presented with reduced MDSCs as well as augmented dendritic cells. Almost all chemotherapeutic medication for GBM has shown no obvious improvement in overall survival in patients. Nevertheless, low-dose chemotherapies were capable of suppressing the levels of MDSCs in GBM as well as multiple tumor models with metastatic to the brain. Thus, MDSCs are potential diagnostic as well as therapeutic biomarkers for GBM patients.

Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy

Biomaterials ◽  
2016 ◽  
Vol 96 ◽  
pp. 47-62 ◽  
Author(s):  
Maria Stella Sasso ◽  
Giovanna Lollo ◽  
Marion Pitorre ◽  
Samantha Solito ◽  
Laura Pinton ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Low Dose ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Lipid Nanocapsules

scholarly journals ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi12-vi13
Author(s):  
David Peereboom ◽  
Justin Lathia ◽  
Tyler Alban ◽  
Alireza Mohammadi ◽  
Manmeet Ahluwalia ◽  
...  
Keyword(s):  
Low Dose ◽  
Suppressor Cells ◽  
Recurrent Glioblastoma ◽  
Myeloid Derived Suppressor Cells ◽  
Phase 0

Myeloid‐derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes

2017 ◽  
Vol 95 (6) ◽  
pp. 538-548 ◽  
Author(s):  
Sílvia Casacuberta‐Serra ◽  
Marta Parés ◽  
Arantxa Golbano ◽  
Elisabet Coves ◽  
Carmen Espejo ◽  
...  
Keyword(s):  
Peripheral Blood ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Blood Monocytes ◽  
Hematopoietic Progenitors ◽  
Peripheral Blood Monocytes

LSC Abstract – Peripheral blood myeloid-derived suppressor cells reflect disease status in IPF

2016 ◽  
Author(s):  
Isis Enlil Fernandez ◽  
Flavia Greiffo ◽  
Marion Frankenberger ◽  
Katharina Heinzelmann ◽  
Claus Neurohr ◽  
...  
Keyword(s):  
Peripheral Blood ◽  
Suppressor Cells ◽  
Disease Status ◽  
Myeloid Derived Suppressor Cells

Significance of myeloid-derived suppressor cells in squamous cell carcinoma of the head and neck.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6070-6070
Author(s):  
Grace G Kim ◽  
Adam M Zanation ◽  
Nicholas A Taylor ◽  
Carol G. Shores ◽  
Karen P McKinnon ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Advanced Cancer ◽  
Squamous Cell ◽  
Peripheral Blood ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Healthy Donors ◽  
Hpv Status

6070 Background: Patients with advanced stage squamous cell carcinoma of the head and neck (SCCHN) have less than 50% 5-year survival rate Human papillomavirus (HPV)-associated SCCHN in oropharyngeal sites have shown better prognosis. Little is known about the role of myeloid-derived suppressor cells (MDSCs) in immune suppression or tumor progression in the setting of SCCHN. Our objective is to evaluate the clinical significance of MDSCs in subjects with SCCHN, HPV-positivity, and advanced cancer staging. Methods: Thirty-three subjects with SCCHN and 10 healthy donors were enrolled in this prospective cohort study. Fresh blood was collected at the time of surgical resection of SCCHN in a tertiary academic center between August 2011 and January 2013. Peripheral blood mononuclear cells (PBMCs) were obtained using Ficoll Hypaque. MDSCs were immunophenotyped as CD14-CD33+CD11b+by flow cytometry. HPV status was determined by in situ hybridization Frequencies of MDSCs in blood of different cohorts were evaluated. Results: Thirty-three subjects (ages 34-83 years, 25 males) with SCCHN were enrolled. Increased numbers of CD14-CD33+CD11b+ cells of total leukocytes were found in HPV-associated SCCHN (median 26.6%, n=11) compared to HPV-negative SCCHN (16.3%, n=19). Interestingly, 3 subjects who previously had HPV-positive SCCHN but with no evidence of disease had 6.24% (n=3) CD14-CD33+CD11b+cells of leukocytes which was higher than healthy donors (3.55%, n=10). Subjects with advanced cancer stages (III-IV) had higher levels of MDSCs (26%, n=19) compared to those with a lower grade (I-II, 15.5%, n=11) regardless of HPV status. Three subjects were lost to follow up. Of the remaining subjects, the overall median follow time was 3 months and subjects who were found to have recurrence, regional or local metastasis had higher frequencies of MDSCs in the blood (26.35%, n=4) compared to those with no evidence of disease (18.5%, n=26) at the time of surgery. Conclusions: This study suggests there is an accumulation of MDSCs in peripheral blood of patients with SCCHN, particularly in HPV-associated SCCHN. Further, increased levels of MDSCs in the peripheral blood are related to more advance cancer stage and poor clinical outcomes.

Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 2543-2543
Author(s):  
Natalia Palazón-Carrión ◽  
Carlos Jiménez-Cortegana ◽  
Esther Holgado ◽  
Josefina Cruz Jurado ◽  
Jose Luis Alonso Romero ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Peripheral Blood ◽  
Suppressor Cells ◽  
Complete Response ◽  
Advanced Breast ◽  
Healthy Population ◽  
Myeloid Derived Suppressor Cells ◽  
Tumor Subtypes ◽  
Disease Stabilization

2543 Background: High levels of myeloid-derived suppressor cells (MDSCs) seem a negative prognostic factor in advanced breast cancer (ABC) patients (pts). Preclinical studies suggest an immunomodulatory effect of some classical anti-tumor agents through alteration of MDSCs homeostasis. We analyzed the association of MDSCs and clinical evolution of ABC pts, taking into account the systemic treatment (tx) modulation of MDSCs levels in pts from two studies (“A”: GEICAM/2015-04 PANGEA-BREAST, NCT03025880 “Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC”, and “B”: PI-0502-2014 “Peripheral blood analyses of immune response induced by 1st line tx of ABC according to clinical guidelines”). Methods: MDSCs (CD33+ CD11b+) levels were determined by flow-cytometry in peripheral blood samples at three time points (basal, at cycles 3 and 6) from: 39 HER2-negative heavily pretreated pts from study “A”, 43 non-pretreated pts (all subtypes) from study “B” and 20 women from a healthy cohort (HC), with no cancer diagnosis. MDSCs levels from the different cohorts were compared and correlated with pts with Clinical Benefit (CB: partial/complete response + disease stabilization) vs pts with Progressive Disease (PD). Results: Tx response was assessed in 33 pts (85%) from study “A” and 39 pts (91%) from study “B”. CB was observed in 11 pts (28%) from study “A” and in 34 (79%) from study “B” while PD was observed in 22 pts (56%) from study “A” and in 5 (12%) from study “B”. Basal MDSCs levels were significantly higher in ABC pts (studies “A”+”B”) than in HC (15.95 vs 0.81 cells/µl, p = 0.009). At cycle 6, MDSCs were considerably lower in pts with CB vs DP (2.90 vs 13.75 cells/µl, p < 0.001). This decrease was more pronounced in study “B” than in study “A” pts (p < 0.001 vs p = 0.074, respectively), probably due to differences in number of events, tumor subtypes and tx between both studies. Conclusions: Our results suggest that ABC pts show alterations in MDSCs and that their decrease along tx may have a positive predictive value, highlighting the importance that immune-competent status may play in the evolution of ABC. MDSCs may represent a target for therapeutic purposes in ABC.

Sign in / Sign up

Export Citation Format

Share Document